ReviewCancer communications (London, England)2022

Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.

Yang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.